Malignant Pleural Mesothelioma

We also summarize ongoing therapeutic strategies targeting MSLN and discuss how TME-driven resistance mechanisms are shaping the next generation of MSLN-directed therapies. By integrating molecular insights with translational perspectives, this work provides a comprehensive overview of MSLN biology and its emerging therapeutic relevance in cancer.

CD68, CD206, PD-L1, and LOXL3 may collaboratively contribute to the regulation of the PM microenvironment and are closely linked to the invasion and metastasis of PM. Therefore, LOXL3 can be used as both a prognostic marker and a potential therapeutic target for PM.

These findings demonstrate that TA-MUC1 has been documented in diverse malignancies, including rare and metastatic presentations. The descriptive evidence supports its potential relevance as a therapeutic target and highlights the need for standardized evaluation and prospective studies.

These multi-omic, scRNA-seq analyses of primary patient tissues provide new candidate drivers of MC state and novel biomarkers to improve patient stratification. Further experimental exploration and clinical validation of these findings may reveal new treatment strategies and refine current clinical decision-making in pleural mesothelioma.

Circulating miRNA signatures represent promising non-invasive biomarkers for early PM detection and prognostic stratification, particularly in epithelioid cases. Incorporation of these biomarkers into clinical workflows could pave the way for more personalized treatment strategies and optimize patient selection for surgery.

Background/Objectives: Despite the introduction of targeted therapies such as Nivolumab, survival outcomes for patients with esophageal adenocarcinoma remain poor. This underscores the urgent need for clinical trials evaluating the efficacy of pegargiminase in this patient population. Additionally, incorporating ASS1 immunohistochemical staining into pre-neoadjuvant biopsy assessments should be considered to optimize neoadjuvant treatment strategies and advance the implementation of personalized cancer therapy.

During the follow-up period of 224-238 days, the experimental pigs remained in good health.​ Based on the study of differentially expressed proteins in malignant pleural mesothelioma under hypoxic and normoxic conditions, the successfully constructed large-scale porcine tumor model can pre-verify the effect of drugs on tumors in different oxygen environments during new drug development, improving screening efficiency and success rate. It can also accurately simulate clinical scenarios, providing experimental support for the efficacy evaluation and scheme optimization of intervention strategies such as chemotherapy, radiotherapy, and immune targeting, thereby effectively promoting the development of clinical treatment for malignant pleural mesothelioma.​.

P1/2, N=19, Completed, CRISPR Therapeutics AG | Recruiting --> Completed | N=250 --> 19 | Trial completion date: May 2030 --> Sep 2025 | Trial primary completion date: Apr 2030 --> Sep 2025

MSLN-TTC showed good tolerability, but the maximum tolerated dose could not be determined due to discontinuations after antidrug antibody formation. Stable disease was observed in 12 out of 36 patients.

MPM should still be considered an important differential diagnosis in young patients presenting with solitary pleural masses and no history of typical asbestos exposure. F-18 FDG PET/CT, while serving as an essential component of initial staging for MPM, has some inherent limitations.

P2, N=126, Not yet recruiting, Intergroupe Francophone de Cancerologie Thoracique

Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer with a poor prognosis, often presenting challenges in treatment. This case suggests that residual IL-6 suppression from prior tocilizumab therapy may attenuate the severity of subsequent irAEs, permitting effective management without compromising anti-tumor efficacy. IL-6 modulation could be a promising strategy to improve the therapeutic index of dual checkpoint inhibition in MPM.